A Phase 1/2 interventional study of Docetaxel and TAK-117 in Non-small Cell Lung Cancer, sponsored by Millennium Pharmaceuticals, Inc.. Terminated at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-07.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda — 1 open to participants now, 4 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Takeda.
Among the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2015, is one of 6 in phase 1/2, and was the 8th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 3
First in 2002; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 101 across the 17 interventional studies, 94 across the 10 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
1 of the studies in Carcinoma, Non-Small-Cell Lung by Takeda that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05735327TakedaA Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY | 2027-04-26 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the recommended phase 2 dose (RP2D) of TAK-117 when administered in combination with docetaxel in participants with non-small cell lung cancer (NSCLC) and to evaluate efficacy, safety, and tolerability of TAK-117 administered alone and in combination with docetaxel at the RP2D in participants with locally advanced or metastatic non-small cell lung cancer.
The drug being evaluated in this study is called TAK-117. TAK-117 is tested in combination with docetaxel versus docetaxel alone for the treatment of non-small cell lung cancer (NSCLC).
This study consisted of 2 phases:
The study enrolled 14 patients with NSCLC who have been treated with multiple prior lines of therapies will be enrolled for Phase 1b. The participants will receive docetaxel (36 mg/m\^2) intravenous (IV) and TAK-117 tablets, orally administered, once daily in 21-day dosing cycles. The TAK-117 dose will be escalated until recommended Phase 2 dose (RP2D) is determined.
Each part of the adaptive Phase 2 portion of the study is designed as a stand-alone, randomized study evaluating PFS as the primary efficacy measure in a total of 60 participants between the 2 treatment arms: TAK-117 plus docetaxel versus docetaxel alone. An event-driven analysis of PFS will be performed after each part of Phase 2. On the basis of the PFS analysis of the preceding part of the study, the study may be stopped for efficacy or futility, or proceed to the next part. However, Phase 2 of the study was cancelled.
Study drug will be administered in 21-day dosing cycles. During each phase of the study, participants will be treated with a maximum of 9 cycles of either docetaxel alone or docetaxel plus TAK-117. Subsequently, participants treated with docetaxel plus TAK-117 may continue to receive TAK-117 monotherapy until progression of disease, occurrence of unacceptable toxicities or death.
The maximum duration of treatment for participants will be 12 months unless it is determined that a participant would derive benefit from continued treatment beyond 12 months. Participants will continue to be followed after discontinuation of study drug to collect PFS and OS data. Participants may withdraw from therapy at any time.
This multicenter trial will be conducted in North America. The overall time to participate in this study is up to 24 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has a and/or cytologically confirmed diagnosis of NSCLC (squamous or nonsquamous).
Has experienced failure of at least 1 prior chemotherapy regimen:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m\^2, intravenous (IV) infusion, on Days 1 and 8 of the 21-day cycle up ro Cycle 9 (approximately 189 days).
Drug: Docetaxel · Drug: TAK-117
TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m\^2, IV infusion, on Days 1 and 8 of the 21-day cycle up to 6 cycles (approximately 126 days).
Drug: Docetaxel · Drug: TAK-117
TAK-117 tablets, at the dose determined in the dose escalation phase, on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of a 21-day cycle plus Docetaxel 36 mg/m\^2 IV infusion on Days 1 and 8 of a 21-day cycle.
Drug: Docetaxel · Drug: TAK-117
Docetaxel 75 mg/m\^2, IV infusion once every 3 weeks (per approved prescribing information) with dosing on Day 1 of each 21-day cycle.
Drug: Docetaxel · Drug: TAK-117
Number of Participants With Dose-Limiting Toxicity (DLT) in Phase 1b
DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 and was defined as any of the following events: 1. Grade 4 neutropenia or thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. ≥Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 4 hematologic toxicity; 6. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 arthralgia/myalgia, ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 Rash, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 1 with appropriate treatment; 7. Inability to administer at least 75% of planned doses; 8. Clinically significant occurrence per investigator that is a safety risk.
Time frame: Cycle 1 (Up to Day 21)
Maximum Tolerated Dose (MTD) of TAK-117 in Combination With Docetaxel 36 mg/m^2 in Phase 1b
The MTD is defined as the dose of TAK-117 in combination with docetaxel 36 mg/m\^2 at which 1 of 6 evaluable participants experience DLT. DLT was evaluated according to NCI CTCAE version 4.03 and was defined as any of the following events: 1. Grade 4 neutropenia or thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. ≥Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 4 hematologic toxicity; 6. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 arthralgia/myalgia, ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 Rash, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 1 with appropriate treatment; 7. Inability to administer at least 75% of planned doses; 8. Clinically significant occurrence per investigator that is a safety risk.
Time frame: Cycle 1 (Up to Day 21)
Recommended Phase 2 Dose of TAK-117 in Phase 1b
The recommended phase 2 dose was determined in Phase 1b based on participant dose-limiting toxicities and the maximum tolerated dose.
Time frame: Cycle 1 (Up to Day 21)
Progression-Free Survival (PFS) in Phase 2
PFS is defined as the time from the date randomization to the date of first documented progressive disease (PD) or death as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.
Time frame: Approximately 12 months in Phase 2
Number of Participants With Significant Change in Vital Signs Reported as Adverse Events in Phase 1b
Clinically significant change from baseline in vital sign measures will be assessed. Vital sign measurements included measurements of diastolic and systolic blood pressure, heart rate, and temperature.
Time frame: First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)
Number of Participants With Significant Change in Physical Examination Reported as Adverse Events in Phase 1b
Physical examination consists of examinations of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; and (11) physical examinations other than body systems described in (1) to (10).
Time frame: First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)
Number of Participants With Electrocardiogram (ECG) Findings Reported as Adverse Events in Phase 1b
A standard 12-lead ECG was performed.
Time frame: First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)
Number of Participants With Clinically Significant Change in Clinical Laboratory Tests Reported as Adverse Events in Phase 1b
The number of participants with any markedly abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout study.
Time frame: First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Phase 1b
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From first dose of study drug to 30 days after last dose of study drug (Up to Day 223)
Number of Participants With Significant Change in Vital Signs Reported as Adverse Events in Phase 2
Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.
Time frame: Approximately 12 months in Phase 2
Number of Participants With Significant Change in Physical Examination Reported as Adverse Events in Phase 2
Physical examination consists of examinations of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; and (11) physical examinations other than body systems described in (1) to (10).
Time frame: Approximately 12 months in Phase 2
Number of Participants With Electrocardiogram (ECG) Findings Reported as Adverse Events in Phase 2
Clinically significant changes from baseline in ECGs will be tabulated by time point including any unscheduled measurements.
Time frame: Approximately 12 months in Phase 2
Number of Participants With Clinically Significant Change in Clinical Laboratory Tests Reported as Adverse Events in Phase 2
The number of participants with any markedly abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout study.
Time frame: Approximately 12 months in Phase 2
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Phase 2
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: Approximately 12 months in Phase 2
Response Rate in Phase 2
Response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.
Time frame: Approximately 12 months in Phase 2
Disease Control Rate in Phase 2
Disease control rate is defined as percentage of participants with CR + PR + stable disease (SD). According to RECIST: CR is defined as disappearance of all target lesions, PR is defined as 30% decrease in the sum of the longest diameter of target lesions and SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter (LD) since the treatment started.
Time frame: Approximately 12 months in Phase 2
Duration of Response in Phase 2
The duration of response is defined as the time from the date of first documentation of a response to the date of first documentation of progression of disease. As per RECIST 1.1, PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.
Time frame: Approximately 12 months in Phase 2
Time to Progression in Phase 2
Time to progression is defined as the time from the date of randomization to the date of first documentation of progression of disease. As per RECIST 1.1, PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.
Time frame: Approximately 12 months in Phase 2
Overall Survival (OS) in Phase 2
Overall survival is defined as the time from the date of randomization to the date of death.
Time frame: Approximately 12 months in Phase 2
TAK-117 Plasma Concentration in Phase 1b
Time frame: Cycle 1 Day 1 pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose
Cmax: Maximum Observed Plasma Concentration for TAK-117
Time frame: Cycle 1 Day 1 pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117
Time frame: Cycle 1 Day 1 pre-dose and up to 24 hours post-dose
AUCtau: Area Under the Concentration Time Curve From Time 0 to the Next Dose in Phase 1b for TAK-117
Time frame: Cycle 1 Day 1 pre-dose and up to 24 hours post-dose
AUC(Last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Phase 1b for TAK-117
Time frame: Cycle 1 Day 1 pre-dose and up to 24 hours post-dose
CL/F: Oral Clearance for TAK-117
Time frame: Cycle 1 Day 1 pre-dose and up to 24 hours post-dose
T1/2: Terminal Phase Elimination Half-life (T1/2) for TAK-117
Time frame: Cycle 1 Day 1 pre-dose and up to 24 hours post-dose
TAK-117 Plasma Concentrations When Administered 1 Day After Docetaxel in Phase 2
Time frame: 1 day post docetaxel dose
Participants took part in the study at 5 investigative sites in United States and 1 in Canada from 03 June 2015 to 20 January 2017. The Phase 2 portion of the study was cancelled by the sponsor.
| Milestone | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 | Phase 2 - TAK-117 + Docetaxel 36 mg/m^2 | Phase 2 - Docetaxel 75 mg/m^2 |
|---|---|---|---|---|
| Started | 6 | 8 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 6 | 8 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by patient | 1 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 2 | 0 | 0 |
| Withdrew: Death due to disease progression | 2 | 2 | 0 | 0 |
| Withdrew: Death from legionella infection | 0 | 1 | 0 | 0 |
| Withdrew: Patient seen by another oncologist | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 and was defined as any of the following events: 1. Grade 4 neutropenia or thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. ≥Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 4 hematologic toxicity; 6. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 arthralgia/myalgia, ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 Rash, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 1 with appropriate treatment; 7. Inability to administer at least 75% of planned doses; 8. Clinically significant occurrence per investigator that is a safety risk.
| participants | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 |
|---|---|---|
| Number of Participants With Dose-Limiting Toxicity (DLT) in Phase 1b | 0 | 1 |
The MTD is defined as the dose of TAK-117 in combination with docetaxel 36 mg/m\^2 at which 1 of 6 evaluable participants experience DLT. DLT was evaluated according to NCI CTCAE version 4.03 and was defined as any of the following events: 1. Grade 4 neutropenia or thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. ≥Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 4 hematologic toxicity; 6. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 arthralgia/myalgia, ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 Rash, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 1 with appropriate treatment; 7. Inability to administer at least 75% of planned doses; 8. Clinically significant occurrence per investigator that is a safety risk.
| mg | TAK-117 + Docetaxel |
|---|---|
| Maximum Tolerated Dose (MTD) of TAK-117 in Combination With Docetaxel 36 mg/m^2 in Phase 1b | 300 |
The recommended phase 2 dose was determined in Phase 1b based on participant dose-limiting toxicities and the maximum tolerated dose.
| mg | TAK-117 + Docetaxel |
|---|---|
| Recommended Phase 2 Dose of TAK-117 in Phase 1b | 200 |
PFS is defined as the time from the date randomization to the date of first documented progressive disease (PD) or death as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.
No measurements were reported for this outcome.
Clinically significant change from baseline in vital sign measures will be assessed. Vital sign measurements included measurements of diastolic and systolic blood pressure, heart rate, and temperature.
| participants | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 |
|---|---|---|
| Bradycardia | 1 | 0 |
| Sinus tachycardia | 0 | 1 |
Physical examination consists of examinations of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; and (11) physical examinations other than body systems described in (1) to (10).
| participants | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 |
|---|---|---|
| Number of Participants With Significant Change in Physical Examination Reported as Adverse Events in Phase 1b | 0 | 1 |
A standard 12-lead ECG was performed.
| participants | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 |
|---|---|---|
| Bradycardia | 1 | 0 |
| Tachycardia | 0 | 1 |
The number of participants with any markedly abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout study.
| participants | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 |
|---|---|---|
| Anemia | 2 | 2 |
| Hypokalemia | 1 | 3 |
| Hypomagnesemia | 0 | 3 |
| Hypophosphatemia | 0 | 3 |
| Aspartate aminotransferase increased | 1 | 2 |
| Febrile neutropenia | 1 | 2 |
| Hyponatremia | 1 | 2 |
| Hyperglycemia | 0 | 2 |
| Leukopenia | 0 | 1 |
| Pancytopenia | 0 | 1 |
| Thrombocytopenia | 1 | 0 |
| Blood creatinine increased | 1 | 1 |
| Alanine aminotransferase increased | 0 | 1 |
| Blood cholesterol increased | 0 | 1 |
| Neutrophil count decreased | 1 | 0 |
| White blood cell count decreased | 0 | 1 |
| Hyperkalaemia | 1 | 0 |
| Hypernatraemia | 0 | 1 |
| Hypoalbuminaemia | 1 | 0 |
| Hypocalcaemia | 0 | 1 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
| participants | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 |
|---|---|---|
| TEAEs | 6 | 8 |
| SAEs | 5 | 6 |
Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.
No measurements were reported for this outcome.
Physical examination consists of examinations of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; and (11) physical examinations other than body systems described in (1) to (10).
No measurements were reported for this outcome.
Clinically significant changes from baseline in ECGs will be tabulated by time point including any unscheduled measurements.
No measurements were reported for this outcome.
The number of participants with any markedly abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout study.
No measurements were reported for this outcome.
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
No measurements were reported for this outcome.
Response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.
No measurements were reported for this outcome.
Disease control rate is defined as percentage of participants with CR + PR + stable disease (SD). According to RECIST: CR is defined as disappearance of all target lesions, PR is defined as 30% decrease in the sum of the longest diameter of target lesions and SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter (LD) since the treatment started.
No measurements were reported for this outcome.
The duration of response is defined as the time from the date of first documentation of a response to the date of first documentation of progression of disease. As per RECIST 1.1, PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.
No measurements were reported for this outcome.
Time to progression is defined as the time from the date of randomization to the date of first documentation of progression of disease. As per RECIST 1.1, PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.
No measurements were reported for this outcome.
Overall survival is defined as the time from the date of randomization to the date of death.
No measurements were reported for this outcome.
| ng/mL | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 |
|---|---|---|
| Predose | 114.00 ± 254.912 | 0.00 ± 0.000 |
| 0.5 Hour Postdose | 1208.60 ± 1080.782 | 847.39 ± 966.346 |
| 1 Hour Postdose | 1907.00 ± 1307.124 | 1973.29 ± 1688.210 |
| 2 Hours Postdose | 2597.83 ± 1612.233 | 3021.43 ± 2162.417 |
| 4 Hours Postdose | 2477.50 ± 1407.465 | 4185.71 ± 2156.439 |
| 6 Hours Postdose | 2143.00 ± 1290.395 | 3648.57 ± 1636.892 |
| 8 Hours Postdose | 1902.50 ± 1210.553 | 3677.14 ± 1941.020 |
| 24 Hours Postdose | 652.17 ± 472.315 | 1771.57 ± 1347.864 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over First dose of study drug through 30 days from the last dose (up to Day 223). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | 1/6 (16.7%) | 5/6 (83.3%) | 6/6 (100%) |
| Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 | 3/8 (37.5%) | 6/8 (75%) | 8/8 (100%) |
| Event | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 |
|---|---|---|
| PneumoniaInfections and infestations | 2/6 | 1/8 |
| DiarrhoeaGastrointestinal disorders | 2/6 | 1/8 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/6 | 0/8 |
| NauseaGastrointestinal disorders | 0/6 | 2/8 |
| VomitingGastrointestinal disorders | 0/6 | 2/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/6 | 2/8 |
| DehydrationMetabolism and nutrition disorders | 0/6 | 2/8 |
| Gastric haemorrhageGastrointestinal disorders | 1/6 | 0/8 |
| StomatitisGastrointestinal disorders | 1/6 | 0/8 |
| Cardio-respiratory arrestCardiac disorders | 1/6 | 0/8 |
| Event | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 |
|---|---|---|
| NauseaGastrointestinal disorders | 2/6 | 5/8 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 5/8 |
| FatigueGeneral disorders | 3/6 | 4/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/6 | 3/8 |
| Decreased appetiteMetabolism and nutrition disorders | 1/6 | 3/8 |
| HypokalaemiaMetabolism and nutrition disorders | 1/6 | 3/8 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/6 | 3/8 |
| HypophosphataemiaMetabolism and nutrition disorders | 0/6 | 3/8 |
| AnaemiaBlood and lymphatic system disorders | 2/6 | 2/8 |
| Oedema peripheralGeneral disorders | 2/6 | 2/8 |
Baseline characteristics were assessed for enrolled participants.
| Age, Continuous(years) | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 | Total |
|---|---|---|---|
| Mean | 64.0 ± 8.10 | 62.1 ± 11.32 | 62.9 ± 9.75 |
| Sex: Female, Male(Participants) | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 5 | 6 | 11 |
| Race/Ethnicity, Customized(Participants) | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 5 | 7 | 12 |
| Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 | Total |
|---|---|---|---|
| White | 4 | 5 | 9 |
| Black or African American | 1 | 2 | 3 |
| Asian | 1 | 0 | 1 |
| Not reported | 0 | 1 | 1 |
| Height(cm) | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 | Total |
|---|---|---|---|
| Mean | 171.53 ± 5.854 | 172.95 ± 6.102 | 172.34 ± 5.810 |
| Weight(kg) | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 | Total |
|---|---|---|---|
| Mean | 69.48 ± 21.630 | 72.69 ± 9.157 | 71.31 ± 15.093 |
| Body Surface Area(m^2) | Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2 | Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2 | Total |
|---|---|---|---|
| Mean | 1.805 ± 0.2987 | 1.865 ± 0.1231 | 1.839 ± 0.2084 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Jan 2017, 19 months.
Results were first posted in Feb 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Serabelisib
Carcinoma, Non-Small-Cell Lung →
Millennium Pharmaceuticals, Inc. →